Clinical Trial Detail

NCT ID NCT02200562
Title Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of Utah
Indications

melanoma

Therapies

Dabrafenib + Ipilimumab

Age Groups: adult

Additional content available in CKB BOOST